Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alx Oncology Holdings (ALXO) Cash & Equivalents (2019 - 2023)

Alx Oncology Holdings' Cash & Equivalents history spans 5 years, with the latest figure at $19.6 million for Q3 2023.

  • For Q3 2023, Cash & Equivalents fell 60.08% year-over-year to $19.6 million; the TTM value through Sep 2023 reached $19.6 million, down 60.08%, while the annual FY2022 figure was $48.8 million, 86.58% down from the prior year.
  • Cash & Equivalents for Q3 2023 was $19.6 million at Alx Oncology Holdings, down from $38.0 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $434.2 million in Q4 2020 and bottomed at $9.0 million in Q4 2019.
  • The 5-year median for Cash & Equivalents is $98.1 million (2020), against an average of $188.9 million.
  • The largest annual shift saw Cash & Equivalents surged 4715.56% in 2020 before it tumbled 87.26% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $9.0 million in 2019, then soared by 4715.56% to $434.2 million in 2020, then decreased by 16.25% to $363.7 million in 2021, then plummeted by 86.58% to $48.8 million in 2022, then plummeted by 59.89% to $19.6 million in 2023.
  • Per Business Quant, the three most recent readings for ALXO's Cash & Equivalents are $19.6 million (Q3 2023), $38.0 million (Q2 2023), and $63.2 million (Q1 2023).